ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Merck & Company (MRK – Research Report). The ...

Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.

Germany's Merck KGaA is betting on partnerships to boost its biopharma business. Speaking with Bloomberg TV on the sidelines ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

The CEO of Germany's Merck KGaA on Thursday said a recovery in sales growth at its existing business means it can take a ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other large-cap value stocks. Why is this Portfolio Manager Cautiously Optimistic? The market ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

The "Cellular Starting Materials Market by Product, by Grade, by End-User, and By Region" report has been added to ...

Merck & Co. Inc. 0.99% $242.04B ...